UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of ~~The~~Report ~~Securities~~(Date ~~Exchange~~of ~~Act~~earliest ofevent ~~1934~~reported): March 11, 2026

Date of Report (Date of earliest event reported): February 11, 2026

Biogen Inc.

(Exact name of registrant as specified in its charter)

Delaware	0-19311	033-~~19311~~0112644	~~33-0112644~~
(State or other jurisdictionof incorporation)		(Commission File Number)	(IRS EmployerIdentification No.)
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

225 Binney Street, Cambridge, Massachusetts 02142

(Address of principal executive offices; Zip Code)

Registrant’s telephone number, including area code: (~~617~~781) ~~679~~464-2000

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	~~TradingSymbol(s)~~Name of each exchange on which registered		~~Name of each exchangeon which registered~~
Common Stock, $0.0005 par value	BIIB	~~BIIB~~The Nasdaq Global Select Market		~~The Nasdaq Global Select Market~~

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

☐ Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On ~~February~~ March 11, 2026, ~~Caroline Dorsa, Chair of the~~ Biogen Inc. (~~“Biogen” or~~ the “Company”) ~~Board of Directors (the “Board”)~~ announced that ~~she~~Susan ~~would~~H. ~~not~~Alexander, ~~stand~~Chief ~~for~~Legal ~~re-election~~Officer, towill ~~the~~depart ~~Board~~from at the ~~2026~~Company ~~Annual~~effective ~~Meeting~~as of ~~Stockholders (~~the ~~“Annual~~end ~~Meeting”)~~May, 2026. ~~Ms. Dorsa’s~~The ~~decision~~Company tohas ~~not~~initiated ~~stand~~a ~~for~~search ~~reelection was not related~~ to ~~any~~identify ~~disagreement with~~ the ~~Board or the~~ Company’s onnext ~~any~~Chief ~~matter~~Legal ~~relating to its operations, policies or practices~~Officer.

Item 8.01 Other Items.

On February 11, 2026, the Board elected Dr. Maria C. Friere to serve as Chair of the Board, effective after the Annual Meeting.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Biogen Inc.

	By:	/s/ Wendell Taylor
		Wendell Taylor
		Secretary

Date: ~~February~~ March 11, 2026

Filing Compare · BIOGEN INC.